Micromet Presents Updated Data on the Phase 1 Trial Studying Blinatumomab (MT103/MEDI-538) in Patients with Advanced Non-Hodgkin's Lymphoma

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Follow-Up Data Presented at the American Society of Hematology (ASH)
Annual Meeting Indicates that Blinatumomab is Able to Induce Durable
Remission in Patients
with Relapsed NHL

Bethesda, MD, December 9, 2008 -- Micromet, Inc. (Nasdaq: MITI), a
biopharmaceutical company developing novel, proprietary antibodies
for the treatment of cancer, inflammation and autoimmune diseases,
today presented an update from its ongoing phase 1 clinical study of
BiTE® antibody blinatumomab (MT103/MEDI-538) in patients with
relapsed non-Hodgkin's lymphoma (NHL) at the 50th annual meeting of
the American Society of Hematology, held December 6 to 9 in San
Francisco, CA. Blinatumomab is a novel therapeutic antibody that
activates a patient's T cells to seek out and destroy cancer cells.

As previously reported, 11 of 27 patients treated at doses of 0.015
mg/m2 per day and higher have responded to treatment with
blinatumomab with partial and complete responses. The responses were
confirmed by a central laboratory using standard Cheson criteria. Of
the seven patients treated at 0.06 mg/m2 per day, all seven have been
in durable remission lasting for at least six months and up to 14
months. Five of the seven responders continue to be in remission. The
most common adverse events (AEs) included lymphopenia, pyrexia, and
leukopenia. The vast majority of AEs occurred early during treatment
and improved or resolved during treatment. Permanent treatment
discontinuation due to AEs occurred in a total of nine patients
resulting from infections, liver enzyme increases and fully
reversible central nervous system events.

"The duration of responses seen after monotherapy of NHL patients
with blinatumomab is very encouraging and may represent a next
breakthrough in targeted therapy after the discovery of rituximab,"
said Ronald Levy, M.D., Professor of Medicine, Chief of the Division
of Oncology, at Stanford University School of Medicine.

"These follow-up data continue to demonstrate blinatumomab's
potential as a single-agent therapy for non-Hodgkin's lymphoma
patients," said Micromet's Senior Vice President and Chief Medical
Officer, Carsten Reinhardt, M.D. "The observation of durable
objective responses to the drug indicates the potential that
blinatumomab and BiTE antibodies in general may have in fighting
cancer."

About BiTE Antibodies

BiTE® antibodies are designed to direct the body's cytotoxic, or
cell- destroying, T cells against tumor cells, and represent a new
therapeutic approach to cancer therapy. Typically antibodies cannot
engage T cells because T cells lack the appropriate receptors for
binding antibodies. Previous attempts have shown the potential of T
cells to treat cancer, but the therapeutic approaches tested to date
have been hampered by cancer cells' ability to escape recognition by
T cells. The use of BiTE antibodies that are specifically designed to
engage T cells for attacking cancer cells may provide a more
effective anti-tumor approach than conventional monoclonal
antibodies.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company
with offices in Bethesda, Maryland and Munich, Germany. The Company
is developing novel, proprietary antibodies for the treatment of
cancer, inflammation and autoimmune diseases. The Company uses its
proprietary BiTE® antibody platform to create a new class of
antibodies that specifically activate T cells from the patient's own
immune system to eliminate cancer cells or other disease-related
cells. Four of the Company's antibodies are currently in clinical
trials, with the remainder of its product pipeline in preclinical
development. The Company's lead program is a BiTE antibody known as
blinatumomab, or MT103. It is in a phase 2 clinical trial for the
treatment of patients with acute lymphoblastic leukemia and a phase 1
clinical trial for the treatment of patients with non-Hodgkin's
lymphoma. Micromet is developing blinatumomab in collaboration with
MedImmune, a subsidiary of AstraZeneca plc. Micromet's second BiTE
antibody in clinical development is MT110, which targets the
epithelial cell adhesion molecule (EpCAM). The Company owns all
rights to MT 110, which is currently in a phase 1 clinical trial for
the treatment of patients with solid tumors. The Company's third
clinical stage antibody is adecatumumab, also known as MT201, a
conventional human monoclonal antibody that targets EpCAM-expressing
solid tumors. Micromet is developing adecatumumab in collaboration
with Merck Serono in a phase 1b clinical trial evaluating
adecatumumab in combination with docetaxel for the treatment of
patients with metastatic breast cancer. Micromet has licensed a
fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals,
Inc. MT293 is being developed in a phase 1 clinical trial for the
treatment of

(more)

patients with cancer. The Company's preclinical programs include
MT203, which is being developed in collaboration with Nycomed. MT203
is a traditional human antibody neutralizing the activity of
granulocyte/macrophage colony stimulating factor (GM-CSF), which has
potential applications in the treatment of inflammatory and
autoimmune diseases, such as rheumatoid arthritis, psoriasis, or
multiple sclerosis. Additional BiTE antibodies, targeting CEA, CD33,
Her2, EGFR and MCSP, respectively, are in different stages of
preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be
materially different from historical results or from any future
results expressed or implied by such forward-looking statements.
These forward-looking statements include statements regarding the
efficacy and intended utilization of our product candidates and the
development of our BiTE antibody technology. You are urged to
consider statements that include the words "may," "potential," or the
negative of those words or other similar words to be uncertain and
forward-looking. Factors that may cause actual results to differ
materially from any future results expressed or implied by any
forward-looking statements include the risk that product candidates
that appeared promising in early research, preclinical studies or
clinical trials do not demonstrate safety and/or efficacy in
subsequent clinical trials, the risk that encouraging results from
early research, preclinical studies or clinical trials may not be
confirmed upon further analysis of the detailed results of such
research, preclinical study or clinical trial, and the risk that
additional information relating to the safety, efficacy or
tolerability of our product candidates may be discovered upon further
analysis of preclinical or clinical trial data. These factors and
others are more fully discussed in Micromet's Quarterly Report on
Form 10-Q for the fiscal quarter ended September 30, 2008, filed with
the SEC on November 6, 2008, as well as other filings by the company
with the SEC.

Any forward-looking statements are made pursuant to Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and, as such, speak only
as of the date made. Micromet, Inc. undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise.

# # #

Contact Information

US Media: European Media:
Andrea tenBroek/Chris Stamm Ludger Wess
(781)-684-0770 +49 (40) 8816 5964
micromet@schwartz-pr.com ludger@akampion.com

US Investors: European Investors:
Susan Noonan Ines-Regina Buth
(212) 966-3650 +49 (30) 2363 2768
susan@sanoonan.com ines@akampion.com

--- End of Message ---

Micromet Inc.
6707 Democracy Boulevard, Suite 505 Bethesda USA

WKN:
A0JMQD; ISIN: US59509C1053;
Listed: Xetra Stars in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2008. All rights reserved.